AVCJ Private Equity & Venture Forum China 2023
The premier private equity & venture forum in China
China World Summit Wing Hotel, Beijing & Online
06
Sep
Sector focus: revival of healthcare
Chinese healthcare investments witnessed a slowdown due to a series of COVID-19 curbs, regional tensions, and updated policies. The long-term importance, defensibility and attractiveness of this sector however has not diminished, and investors are returning to companies in the sector. Hot spots include innovative medications in the pharmaceutical sector and biotechnology startups. Our panel of healthcare experts will assess the industry outlook and provide their predictions for the next 12 months.
- How have private equity and venture capital investments in healthcare fared in the past year, and where are the continued opportunities in the sector?
- How will regulatory policy changes affect dealmaking in the sector?
- What are some potential sub-sectors that investors should be on the lookout for?
- How are GPs applying AI and machine learning into their companies in the healthcare sector?
-
SpeakersJenny Yao Partner, Head of Healthcare China KPMG
Sean He Partner NOVO HOLDINGS
Meng Jiang Senior Managing Director and Head of Venture CBC GROUP
James Huang Founding Managing Partner, PANACEA HEALTHCARE VENTURE Managing Partner, KPCB CHINA
Confirm cancellation
Something went wrong.
An error occurred trying to play the stream. Please reload the page and try again.
CloseSign-up to join the ION Analytics Community to:
- Register for events
- Access market insights
- Download reports
Sean joined Novo Holdings in May 2022 as Partner and Head of China.
He has 10 years of healthcare investment experience. Prior to Novo Holdings, Sean was employed as a Principal at Advent International, leading healthcare investing in China. Prior to Advent International, he worked at Warburg Pincus, where he spent five years focusing on investment in healthcare primarily in China and other key Asia markets. Sean started his investing career at CITIC Capital, a control focused private equity firm in China. Before investing, Sean worked in the investment banking division at UBS.
Sean holds a dual BA in English Literature and Economics from Beijing Foreign Studies University.
Meng has over 18 years of investment, M&A and investment banking experience. She has been at CBC Group since the beginning in early 2014, and has led investments in the pharmaceutical sector, including CMAB, I-MAB, and Innovent, among others. Meng spearheaded the launch of the firm’s Venture Capital strategy, which she currently heads.
Prior to CBC Group, Meng was most recently Director and COO at Far East Horizon’s Investments Group where she was responsible for department operations, risk management, and establishing and implementing budgets. For two years, Meng led teams on M&A and minority healthcare services investments. Prior to joining Far East Horizon, Meng was Managing Director at ARC China, where she established its China operations and headed various investments across multiple sectors. Before her time at ARC China, Meng was an Associate Director at Business Development Asia in Shanghai where she executed numerous joint ventures, acquisition and divestiture transactions in the chemical, consumer, and manufacturing sectors in China and Japan. Meng started her career at UBS Investment Bank in New York, where she worked on origination and execution of M&A, IPO, Debt and Equity issuances.
Meng graduated with Honours in Economics and Political Science from Wellesley College.
James Huang is Founding Managing Partner of Panacea Healthcare Venture Capital (RMB 615m Fund & USD180.5m Fund). He has devoted his passion、diligence、intelligence and loyalty into life science and investment industry over 30 years. He is a successful entrepreneur、investor and an opinion leader in Venture Capital healthcare sector in China. Panacea Venture is focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide.
James Huang is also managing partner of Kleiner Perkins Caufield & Byers China. He joined the firm in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. James has made more than 15 investments in China since 2007.
Prior to that, James was a Managing Partner at Vivo Ventures, a Venture Capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).
James is Chairman of Board at Kindstar Global, JHL Biotech and XW Laboratory and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, CASI and Omni Pharmaceuticals.
James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.